Plasma lipids affect dabigatran etexilate anticoagulation in rats with unbalanced diabetes mellitus: 在失衡的糖尿病大鼠中血脂可以影响达比加群酯的抗凝作用
… Accordingly, the aim of the present study was to investigate anticoagulant responses to the
direct thrombin inhibitor dabigatran etexilate (DE) and to identify biological predictors of this …
direct thrombin inhibitor dabigatran etexilate (DE) and to identify biological predictors of this …
关节置换术后抗凝药物预防深静脉血栓及相关并发症的临床研究进展.
徐祎骏， 肖军， 张洋， 史占军 - Progress in Modern …, 2016 - search.ebscohost.com
… Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran
etexilate [J]. Clin Pharmacokinet, 2008, 47(… Oral dabigatran etexilate vs. subcutaneous …
etexilate [J]. Clin Pharmacokinet, 2008, 47(… Oral dabigatran etexilate vs. subcutaneous …
[PDF][PDF] 达比加群酯用于预防心房颤动患者脑卒中时致消化道出血的危险因素与预防措施
曾莉莉， 张云琛， 陈惠弟， 赵佳丽 - 中国新药与临床杂志(Chin J New …, 2016 - core.ac.uk
… Dabigatran etexilate, a new direct thrombin inhibitor, has precise clinical curative effect on
… strategies of gastrointestinal bleeding with dabigatran etexilate for stroke in atrial fibrillation …
… strategies of gastrointestinal bleeding with dabigatran etexilate for stroke in atrial fibrillation …
[HTML][HTML] 新型口服抗凝药的药物基因组学研究进展
陈安妮， 范成龙， 范国荣， 李琴 - 第二军医大学学报, 2020 - html.rhhz.net
… 新型口服抗凝药(new oral anticoagulant,NOAC)包括直接凝血酶(Ⅱ因子)抑制剂和Ⅹa因子抑制
剂,前者代表药物为达比加群酯(dabigatran etexilate,DABE),后者代表药物为利伐沙班,阿哌沙班…
剂,前者代表药物为达比加群酯(dabigatran etexilate,DABE),后者代表药物为利伐沙班,阿哌沙班…
抗凝药物在经颈静脉肝内门体分流术后的应用
蒋明远， 黄华， 路明亮， 林凡榆， 张映媛 - 临床肝胆病杂志, 2018 - lcgdbzz.org
: 经颈静脉肝内门体分流术(TIPS) 经过近30 年的不断探索与发展, 目前已被广泛应用于治疗门静脉
高压并发症, TIPS 在急性食管胃底静脉曲张破裂出血, 预防再出血, 顽固性腹腔积液, 布加综合…
高压并发症, TIPS 在急性食管胃底静脉曲张破裂出血, 预防再出血, 顽固性腹腔积液, 布加综合…
口服抗凝药的临床治疗研究进展.
孟璐， 丁琮洋， 安静， 李亚静， 李颖… - Pharmaceutial Care & …, 2019 - search.ebscohost.com
… New oral anticoagulants ,such as rivaroxaban , apisaban ,edoxaban ,betroxaban and
dabigatran etexilate ,are superior to warfarin ,because of the advantages of no frequent dos唱 age …
dabigatran etexilate ,are superior to warfarin ,because of the advantages of no frequent dos唱 age …
[PDF][PDF] 达比加群酯抗凝治疗的安全性研究进展
徐蕾， 杨婉花 - 世界临床药物, 2016 - jwph.com.cn
… This review describes the adverse reactions of dabigatran etexilate, the limitations of …
Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor…
Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor…
[PDF][PDF] 我国已上市新型抗凝药物的特点及临床应用进展
尤国皎， 都丽萍， 陈跃鑫， 梅丹 - 临床药物治疗杂志, 2017 - lcywzlzz.com
… Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor
dabigatran etexilate[J]. Clin … The pharmacokinetics, pharmacodynamics and tolerability of …
dabigatran etexilate[J]. Clin … The pharmacokinetics, pharmacodynamics and tolerability of …
新型口服抗凝药物在非瓣膜性心房颤动患者中的应用及挑战
刘岳， 任怡荣， 朱火兰， 汪芳 - 中国全科医学, 2020 - chinagp.net
… ,pharmacokinetics, and pharmacodynamics of dabigatran etexilate,an oral direct thrombin
inhibitor[J].Clin … Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban[J].Clin …
inhibitor[J].Clin … Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban[J].Clin …
[HTML][HTML] 吲哚布芬预防老年髋关节置换术后下肢深静脉血栓的临床研究
胡鸿鹏， 刘泽明， 高勇岗， 马文辉… - 中华老年骨科与 …, 2019 - zhlngkykfdzzz.cma-cmc.com.cn
… Clinical study of indolbufen in preventing deep vein thrombosis of lower extremity after hip
… of the oral direct thrombin inhibitor dabigatran etexilate [J]. Clin Pharmacokinet, 2008, 47(5):…
… of the oral direct thrombin inhibitor dabigatran etexilate [J]. Clin Pharmacokinet, 2008, 47(5):…